Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)

NCT04115254 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT04115254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04115254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)
Lead sponsor
Dana-Farber Cancer Institute
Phase
Not applicable
Overall status
Recruiting
Start date
October 22, 2019
Completion date
June 30, 2028
Enrollment
397 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adrenal metastases, borderline resectable pancreatic carcinoma, brain metastases, liver metastases, lung cancer, mesothelioma, metachronous nodal metastases, oligoprogressive nodal metastases, pancreas cancer, prostate cancer, renal cancer, spine metastases, synchronous nodal metastases